EFFECT OF IRBESARTAN IN HYPERTENSIVES WITH TYPE II DIABETES AND NEPHROPATHY

$22,028M01FY2000RRNIH

University Of Iowa, Iowa City IA

Investigators

Linked publications & trials

Paper 39243208 Paper 37886508 Paper 37546769 Paper 36876186 Paper 36763987 Paper 35728925 Paper 33972687 Paper 33578032 Paper 33478957 Paper 33109505 Paper 33068254 Paper 33002231 Paper 32459739 Paper 32446491 Paper 32111975 Paper 32105364 Paper 32091961 Paper 31896075 Paper 31668963 Paper 31505070 Paper 31404238 Paper 31170114 Paper 30737489 Paper 30638821 Paper 30631138 Paper 30580683 Paper 30557192 Paper 30236904 Paper 30157107 Paper 30151617 Paper 29962091 Paper 29939946 Paper 29872859 Paper 29752831 Paper 29266310 Paper 29108124 Paper 29083059 Paper 28915225 Paper 28738135 Paper 28671327 Paper 28647272 Paper 28574873 Paper 28517028 Paper 28259744 Paper 28199816 Paper 27870462 Paper 27804242 Paper 27716862 Paper 27655806 Paper 27594811 Paper 27455401 Paper 27440911 Paper 27423510 Paper 27154016 Paper 27074126 Paper 26861036 Paper 26575079 Paper 26538514 Paper 26400088 Paper 26289232 Paper 26233184 Paper 26198477 Paper 25984811 Paper 25955750 Paper 25751769 Paper 25691513 Paper 25567102 Paper 25300146 Paper 25277841 Paper 25198001 Paper 25177899 Paper 25142616 Paper 25093507 Paper 24979394 Paper 24934607 Paper 24837241 Paper 24821002 Paper 24769221 Paper 24751988 Paper 24723495 Paper 24687018 Paper 24632502 Paper 24590464 Paper 24569989 Paper 24470542 Paper 24370654 Paper 24330321 Paper 24329191 Paper 24231628 Paper 24157931 Paper 24067395 Paper 23889610 Paper 23780579 Paper 23702309 Paper 23470296 Paper 23443723 Paper 23442568 Paper 23418096 Paper 23376047 Paper 23342550

Abstract

The goal of the study is to determine whether irbesartan, an angiotensin II receptor antagonist, will increase the time to doubling of serum creatinine, end-stage renal disease or death compared to placebo or amlodipine in hypertensive patients with diabetic nephropathy.

View original record on NIH RePORTER →